Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Gilead Strikes Hepatitis Drug Deal With CVS Health

Gilead Sciences struck back on Monday against its rival AbbVie in a budding marketing war over costly hepatitis C drugs, winning exclusive access to many patients whose prescriptions are managed by CVS Health.

Published
07 January 2015
From
New York Times
Express Scripts explains exclusive AbbVie hepatitis C prescribing deal

Last month, Express Scripts, the nation’s biggest pharmacy benefits manager, and AbbVie reached an exclusive deal that ushered in a price war for hepatitis C treatments. The drug maker offered an undisclosed discount in hopes of breaking the lock that Gilead Sciences has on the burgeoning market.

Published
07 January 2015
From
Wall Street Journal
Experimental siRNA therapy lowers HBsAg levels in people with hepatitis B

ARC-520, a novel therapy using short interfering RNA, appeared safe and was associated with a reduction in hepatitis B surface antigen levels in people with chronic hepatitis

Published
06 January 2015
By
Liz Highleyman
Third of 2015 health basket expansion in Israel goes to hepatitis C

The Israeli Health Ministry will devote 100 million shekels (£16.6m), roughly a third of the NIS 324m (£53.7m). budget for additions to the 2015 health basket, to medications for treating viral hepatitis.

Published
04 January 2015
From
Jerusalem Post
First of its kind HIV/hepatitis C (HCV) co-infection guide to help curb increasing prevalence and mortality in the UK launched

The ChemSex and hepatitis C: a discussion guide for HCPs has been developed by 56 Dean Street's David Stuart, who has a wealth of experience in providing drug addiction services to HIV/HCV co-infected MSM. The guide, endorsed by The Hepatitis C Trust, is based on over 500 conversations with MSM, aims to inform healthcare professionals and services providers across the UK around ChemSex (the use of recreational drugs for sex) and HIV/HCV co-infection to empower them to use the terminology that will most resonate with these at-risk groups, and to ensure they are being diagnosed and treated effectively.

Published
29 December 2014
From
56 Dean Street, via Medical News Today
More Evidence That HIV-Negative Gays Contract Hep C Via Sex

Increasing evidence suggests that hepatitis C transmits sexually among HIV-negative men who have sex with men, and not just among HIV-positive MSM.

Published
26 December 2014
From
AIDSMeds
Even with New AbbVie Drug, Many Hepatitis C Patients Are Being Turned Away from Treatment

Even with New AbbVie Drug, Many Hepatitis C Patients Are Being Turned Away from Treatment. Doctors, insurance companies, and even governments have cried foul over high prices the new medications Sovaldi, Harvoni, and now Viekira Pak. Sick people aren’t getting the treatments they need due to insurance denials and other roadblocks.

Published
23 December 2014
From
Hepatitis C News
Gilead slides after hepatitis drug setback

Gilead Sciences shares backtracked from their giddy ascent of the past three years, falling more than 10 per cent after the company’s flagship hepatitis C treatment fell out of favour with the largest pharmacy benefits manager in the US. Express Scripts, which helps manage the cost of healthcare plans offered by companies as well as some government programmes, said it had chosen Viekira Pak, a medicine developed by drugmaker AbbVie, as the “exclusive option” for patients.

Published
23 December 2014
From
Financial Times (free registration required)
New open-access journal in the rapidly developing field of virus eradication

The Journal of Virus Eradication is a new open-access online and print journal dedicated to the rapidly developing field of virus eradication. It is particularly interested in publishing original research on HIV, hepatitis viruses, HPV, herpes and flu but work on other viruses is also included. The first issue was successfully launched at the HIV and Hepatitis Five Nations Conference in London on 8 December 2014 and is available now on the Journal website: www.viruseradication.com

Published
23 December 2014
From
Mediscript
Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus

A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study

Published
22 December 2014
By
Liz Highleyman

Filter by country